The Aviva and Foxconn-backed respiratory system developer beat the target for its series D round to bring its total funding to over $150m.

Owlstone Medical, a UK-based respiratory diagnostics technology developer backed by insurance firm Aviva and manufacturing services provider Foxconn, raised $58m in series D funding on Tuesday.

Venture capital firm Horizon Ventures led the round, which surpassed Owlstone’s $50m target and included unnamed investors from the US, Asia and the Middle East, bringing the company’s total funding to over $150m.

Founded in 2016 after spinning off from Owlstone – a chemical detection technology provider – Owlstone Medical is developing diagnostic devices…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn